MYGNHIGH SIGNALFINANCIAL10-K

MYGN reported a catastrophic deterioration in profitability with operating losses more than tripling to $387.2M despite positive operating cash flow generation.

The massive 213% increase in operating losses combined with a 47% decline in stockholders' equity signals severe operational distress that could threaten the company's long-term viability. While positive operating cash flow of $1.8M provides some relief, it's insufficient to offset the magnitude of losses eating away at shareholder value.

Comparing 2026-02-24 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

MYGN's financial position deteriorated dramatically with operating losses exploding from $123.5M to $387.2M while net losses nearly tripled to $365.9M, causing stockholders' equity to collapse by 47% to $368.0M. Despite this operational carnage, the company surprisingly generated positive operating cash flow of $1.8M (versus negative $8.7M prior year) and increased cash reserves by 46% to $149.6M, though total assets still contracted 31%. The stark disconnect between massive accounting losses and positive cash generation, combined with the severe equity erosion, suggests either significant non-cash charges or unsustainable cash flow timing that investors should scrutinize carefully.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-213.5%
-$123.5M-$387.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-187.4%
-$127.3M-$365.9M

Net income declined 187.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
+120.7%
-$8.7M$1.8M

Operating cash flow surged 120.7% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-47.5%
$701.1M$368.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
+46.1%
$102.4M$149.6M

Cash position surged 46.1% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
-31.2%
$1.0B$706.6M

Total assets contracted 31.2% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-18.5%
$164.1M$133.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
+11.6%
$298.0M$332.6M

Current assets grew 11.6% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
+11.3%
$514.7M$572.9M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Inventory
Balance Sheet
+11.3%
$27.5M$30.6M

Inventory built 11.3% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-28
ADDED
As of February 19, 2026, the registrant had 93,508,165 shares of common stock outstanding.
BUSINESS Overview and Mission Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all.
We develop and commercialize molecular tests that help patients and providers uncover genetic insights.
Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.
Our long-term growth str ategy is buil t on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine.
+7 more — sign up free →
REMOVED
As of February 21, 2025, the registrant had 91,309,064 shares of common stock outstanding.
BUSINESS Overview and Mission We are a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.
We develop and offer molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower health care costs.
Our molecular tests provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease.
Our focus is on innovation and growth in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Pharmacogenomics.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →